Trial Profile
A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of the Anti-GM-CSF Monoclonal Antibody KB003 in Subjects With Active Rheumatoid Arthritis and Inadequate Prior Treatment Outcome From Biologic Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenzilumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Humanigen
- 07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
- 27 Jan 2011 Planned end date changed from May 2011 to Mar 2013 as reported by ClinicalTrials.gov.
- 27 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.